Cirrhosis progresses in stages, from a compensated phase with few symptoms to a decompensated phase with serious ...

Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the bile ducts of the liver. Researchers ...

This investigation of 23 patients with the clinical syndrome of "primary biliary cirrhosis" was undertaken to elucidate the morphologic nature of the hepatic alterations, including their etiology ...

Primary biliary cirrhosis (PBC) is a chronic, cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, resulting in chronic cholestasis, portal inflammation ...

Most people have never heard of primary biliary cholangitis (PBC), but the progressive, rare cholestatic liver disease can ...

The association between celiac disease and primary biliary cirrhosis is well established. The breakdown of gut–liver axis equilibrium plays a central role in the development of immune disorders ...

INT-747 is currently being tested in Phase II clinical trials for the treatment of cholestasis in subjects with primary biliary cirrhosis (ClinicalTrials.gov database identifier NCT00570765), and ...

Your doctor may recommend a combination of medications, dietary supplements, and lifestyle changes to help manage primary biliary cholangitis (PBC). Some people eventually need a liver transplant ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis ... leading to cirrhosis. It affects around 130,000 people in the US ...